Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment Massimo BrecciaFrancesca PalandriFrancesco Landi Review Article 22 February 2018 Pages: 745 - 754
Sleep-disordered breathing in patients with sickle cell disease Vikram M. RaghunathanPeter L. WhitesellSeah H. Lim Review Article 06 December 2017 Pages: 755 - 762
A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia David Martínez-CuadrónBlanca Boludaon behalf of the CETLAM and PETHEMA groups Original Article 02 February 2018 Pages: 763 - 772
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation Alissa MarhällFlorian HeidelLars Rönnstrand Original Article Open access 25 January 2018 Pages: 773 - 780
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study Guoqing WeiYongxian HuHe Huang Original Article 07 February 2018 Pages: 781 - 789
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL) Roberta Di BlasiChiara Cattaneoon the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia) Original Article 07 February 2018 Pages: 791 - 798
Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL Hong-Yan ZhaoYang SongYuan Kong Original Article 10 February 2018 Pages: 799 - 811
Prognostic risk models for transplant decision-making in myelofibrosis Juan-Carlos Hernández-BoludaArturo PereiraFrancisco Cervantes Original Article 25 January 2018 Pages: 813 - 820
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review Emanuele CenciniAlberto FabbriMonica Bocchia Original Article 16 January 2018 Pages: 821 - 829
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma Guillemette FouquetLionel KarlinXavier Leleu Original Article 12 January 2018 Pages: 831 - 837
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma Iris BreitkreutzKlaus PodarMarc S. Raab Original Article 23 January 2018 Pages: 839 - 849
Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma Ying ChenDavid R. LairsonXianglin L. Du Original Article 15 January 2018 Pages: 851 - 863
PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft Ping ChenXiaofang WenHuifang Huang Original Article 15 February 2018 Pages: 865 - 875
Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Kana MatsudaShoko OnoNaoya Sakamoto Original Article 16 January 2018 Pages: 877 - 883
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications Igor StomaIgor KarpovAnatoly Uss Original Article 29 January 2018 Pages: 885 - 891
Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India Tridip ChatterjeeAmit ChakravartySudipa Chakravarty Original Article 17 February 2018 Pages: 893 - 898
Polyneuropathy and myopathy in beta-thalassemia major patients P. NemtsasM. ArnaoutoglouA. Orologas Original Article 09 February 2018 Pages: 899 - 904
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma Marcel NijlandTom van MeertenArjan Diepstra Letter to the Editor 11 January 2018 Pages: 905 - 907
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization Saki MinodaTakashi AkasakaHitoshi Ohno Letter to the Editor 01 February 2018 Pages: 909 - 911
Infections associated with ruxolitinib: study in the French Pharmacovigilance database Pinel SylvineSternjacob ThomasThe French Network of Regional Pharmacovigilance Centers Letter to the Editor 16 January 2018 Pages: 913 - 914
Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma Hugo J.A. AdamsThomas C. Kwee Letter to the Editor 12 January 2018 Pages: 915 - 916
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia Yutaro SuzukiJunji KoyaMineo Kurokawa Letter to the Editor 07 February 2018 Pages: 917 - 919
Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein Lisa TachikiZhao Ming DongNicholas Burwick Letter to the Editor 06 February 2018 Pages: 921 - 922
Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia David Martínez-CuadrónBlanca Boludaon behalf of the CETLAM and PETHEMA groups Correction 23 February 2018 Pages: 923 - 923
